MedTrace Logo

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

NCT00606866 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2023-11-29

No results posted yet for this study

Summary

The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

placebo

Placebo for four weeks

DRUG

Sorafenib

Sorafenib 200 mg twice daily

DRUG

Sorafenib

Sorafenib, 400 mg twice daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2007-01-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606866 on ClinicalTrials.gov